[go: up one dir, main page]

ES2053990T3 - Composiciones de acidos grasos esenciales. - Google Patents

Composiciones de acidos grasos esenciales.

Info

Publication number
ES2053990T3
ES2053990T3 ES89305345T ES89305345T ES2053990T3 ES 2053990 T3 ES2053990 T3 ES 2053990T3 ES 89305345 T ES89305345 T ES 89305345T ES 89305345 T ES89305345 T ES 89305345T ES 2053990 T3 ES2053990 T3 ES 2053990T3
Authority
ES
Spain
Prior art keywords
essential fatty
compositions
fatty acids
fatty acid
acid selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89305345T
Other languages
English (en)
Inventor
David Frederick Horrobin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Application granted granted Critical
Publication of ES2053990T3 publication Critical patent/ES2053990T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO Y PREPARACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE LA ESQUIZOFRENIA Y/O DISCINESIA ASOCIADA MEDIANTE COMBINACION DE UNA ACIDO GRASO ESENCIAL ELEGIDO DEL GLA Y DE ACIDOS DE SENE MAYORES DE N - 6 CON UN ACIDO GRASO ESENCIAL ELEGIDO ENTRE EL ACIDO ESTEARIDONICO Y ACIDOS DE SERIE MAYORES DE N - 3 EN CANTIDADES DIARIAS EFECTIVAS DE 10 Y 50 MG DE CADA ACIDO.
ES89305345T 1988-06-10 1989-05-26 Composiciones de acidos grasos esenciales. Expired - Lifetime ES2053990T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888813766A GB8813766D0 (en) 1988-06-10 1988-06-10 Essential fatty acid compositions

Publications (1)

Publication Number Publication Date
ES2053990T3 true ES2053990T3 (es) 1994-08-01

Family

ID=10638418

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89305345T Expired - Lifetime ES2053990T3 (es) 1988-06-10 1989-05-26 Composiciones de acidos grasos esenciales.

Country Status (13)

Country Link
US (2) US4977187A (es)
EP (2) EP0347056B1 (es)
JP (1) JP2796838B2 (es)
KR (1) KR0129666B1 (es)
AT (1) ATE87825T1 (es)
AU (2) AU618814B2 (es)
CA (1) CA1334004C (es)
DE (1) DE68905863T2 (es)
ES (1) ES2053990T3 (es)
GB (1) GB8813766D0 (es)
IE (1) IE63303B1 (es)
NZ (1) NZ229423A (es)
ZA (1) ZA894380B (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US6103755A (en) * 1990-05-22 2000-08-15 Bumann; Harold Foodstuff with prophylactic and/or healing effect and process for its production
DK0457950T3 (da) * 1990-05-23 1994-03-07 Nestle Sa Anvendelse af stearidonsyre til behandling af inflammatorisk betingede sygdomme
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB9026648D0 (en) * 1990-12-07 1991-01-23 Efamol Holdings Nutrition
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
BR9205526A (pt) * 1991-01-24 1994-04-19 Martek Corp Sociedade Norte Am Misturas de oleos microbianos e usos dos mesmos
US5614561A (en) * 1991-03-01 1997-03-25 Warner-Lambert Company Antihistamine-wound healing compositions and methods for preparing and using same
US5646190A (en) * 1991-03-01 1997-07-08 Warner-Lambert Company Acne treating-wound healing compositions and methods for preparing and using same
US5663208A (en) * 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5692302A (en) * 1991-03-01 1997-12-02 Warner-Lambert Company Razor cartridges comprising wound healing compositions and methods for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
US5641814A (en) * 1991-03-01 1997-06-24 Warner-Lambert Company Antikeratolytic-wound healing compositions and methods for preparing and using same
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
PH31403A (en) * 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
KR930006432B1 (ko) * 1991-04-10 1993-07-16 주식회사 우방랜드 아이코사펜타노산 및 α-리놀렌산을 함유하는 여드름 치료제 조성물
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
FR2679109B1 (fr) * 1991-07-18 1994-03-11 Institut Recherche Biologique Sa Nouveaux complements nutritionnels ou dietetiques anti-vieillissement a base d'acide gras poly-insature.
JPH07114761B2 (ja) * 1991-08-29 1995-12-13 ジェクス株式会社 皮膚清拭用品
US5436269A (en) * 1991-11-14 1995-07-25 Sagami Chemical Research Center Method for treating hepatitis
JP3506701B2 (ja) * 1991-11-26 2004-03-15 ワーナー−ランバート・カンパニー 創傷治癒組成物，その調製方法と使用
US5260465A (en) * 1991-12-16 1993-11-09 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
NL9201438A (nl) * 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9301446D0 (en) * 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
FR2704390B1 (fr) * 1993-04-29 1995-06-02 Boiron Complément nutritionnel absorbable per-os destiné à améliorer la peau.
CA2596241C (en) * 1993-06-09 2011-04-19 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
US5668174A (en) * 1993-12-29 1997-09-16 Kowa Tekuno Sachi Co., Ltd. Method of treating hyperparathyroidism
EP0767161B1 (en) * 1994-06-22 1999-11-03 Asahi Kasei Kogyo Kabushiki Kaisha Process for producing methacrolein
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US6340485B1 (en) * 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
DE69724629T2 (de) * 1996-06-03 2004-07-29 Croda International Plc., Goole Zusammensetzungen und deren verwendungen
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
AU731692C (en) 1996-10-11 2001-10-11 Scarista Limited Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
GB9724783D0 (en) * 1997-11-24 1998-01-21 Inst Arable Crops Research Novel polypeptides
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
JP2004527501A (ja) 2001-03-05 2004-09-09 ピー． アーネスト，スティーヴン 経腸処方
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
US8552054B2 (en) * 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
JP2004536059A (ja) * 2001-05-14 2004-12-02 マーテック バイオサイエンシズ ボールダー コーポレーション 微生物、遺伝的に改変された植物種子および海洋生物由来のω−３および／またはω−６高度不飽和脂肪酸を含有する極性脂質の豊富な画分の生成および使用
WO2002092073A1 (en) * 2001-05-14 2002-11-21 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
FR2833174B1 (fr) * 2001-12-06 2004-05-28 Margaret Bronnert Pommade grasse d'origine animale destinee a soulager des demangeaisons et irritations de la peau dues aux dermites, eczema atopique et psoriasis,secheresse cutanee et hyperkeratinose
NZ535549A (en) * 2002-03-08 2006-02-24 Monsanto Technology Llc Treatment and prevention of inflammatory disorders
JP2005532394A (ja) * 2002-07-02 2005-10-27 ガリレオ ファーマシューティカルズ， インコーポレイティド 雌性被験体における炎症性症状および／またはバイオマーカーの低減のための組成物および方法
US7029712B1 (en) * 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
WO2004012753A1 (en) * 2002-07-31 2004-02-12 Helfried Hans Rudolf Crede Pharmaceutical composition containing black cumin oil, flax oil and borago oil
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20160158261A1 (en) * 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
AR045290A1 (es) 2003-08-21 2005-10-19 Monsanto Technology Llc Acido graso desaturasas de primula
WO2005063231A2 (en) * 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20090215896A1 (en) * 2004-01-19 2009-08-27 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
SK50802006A3 (sk) * 2004-03-12 2007-03-01 Egis Gy�gyszergy�r Nyrt. Kombinovaná farmaceutická kompozícia na inhibíciupoklesu kognitívnych funkcií
US7390507B2 (en) * 2004-04-13 2008-06-24 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
CN1968688A (zh) 2004-04-16 2007-05-23 孟山都技术有限公司 脂肪酸去饱和酶在玉米中的表达
KR100580070B1 (ko) * 2004-07-07 2006-05-16 주식회사 엘지생활건강 피부 미백용 식품 조성물
DE602005021675D1 (de) 2004-11-04 2010-07-15 Monsanto Technology Llc Verfahren zur herstellung von ölzusammensetzungen
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US7790953B2 (en) 2006-03-10 2010-09-07 Monsanto Technology Llc Soybean seed and oil compositions and methods of making same
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US20110166229A1 (en) * 2008-09-09 2011-07-07 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9480271B2 (en) 2009-09-15 2016-11-01 Monsanto Technology Llc Soybean seed and oil compositions and methods of making same
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US20120252888A1 (en) 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
WO2012153832A1 (ja) 2011-05-12 2012-11-15 日本水産株式会社 炎症性疾患用皮膚外用組成物
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
CN112980897A (zh) 2013-12-04 2021-06-18 日本水产株式会社 含有二高-γ-亚麻酸的微生物油的制备方法
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
US12048681B2 (en) 2021-08-09 2024-07-30 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1082624A (en) * 1965-02-26 1967-09-06 Calmic Ltd Improvements in or relating to therapeutically active compounds
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
DE3644677A1 (de) * 1986-12-30 1988-07-14 Mohamed Roshdy Dr Ismail Mittel zur verbesserung der bluteigenschaft
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions

Also Published As

Publication number Publication date
AU3597489A (en) 1989-12-14
EP0347056B1 (en) 1993-04-07
US5120760A (en) 1992-06-09
DE68905863T2 (de) 1993-08-26
AU7943491A (en) 1991-09-12
GB8813766D0 (en) 1988-07-13
KR0129666B1 (ko) 1998-04-09
AU618814B2 (en) 1992-01-09
CA1334004C (en) 1995-01-17
IE891819L (en) 1989-12-10
KR900000078A (ko) 1990-01-30
EP0454102A3 (en) 1992-01-02
AU633442B2 (en) 1993-01-28
JP2796838B2 (ja) 1998-09-10
EP0347056A1 (en) 1989-12-20
NZ229423A (en) 1992-10-28
ZA894380B (en) 1990-02-28
JPH0232017A (ja) 1990-02-01
EP0454102A2 (en) 1991-10-30
US4977187A (en) 1990-12-11
ATE87825T1 (de) 1993-04-15
IE63303B1 (en) 1995-04-05
DE68905863D1 (de) 1993-05-13

Similar Documents

Publication Publication Date Title
ES2053990T3 (es) Composiciones de acidos grasos esenciales.
PT956013E (pt) Preparacao farmaceutica compreendendo acido eicosapentaenoico e/ou acido estearidonico
AU586892B2 (en) Pharmaceutical and dietary composition
ES2060290T3 (es) Composiciones de acidos grasos esenciales (efa) y terapia.
PT774962E (pt) Utilizacao de dha como uma composicao farmaceutica
NZ516101A (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
HUT52341A (en) Method for producing preparations
IT8423086A1 (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
DE60008127D1 (de) Diät mit hohem lipidgehalt
AU1821888A (en) Treatment or prevention of memory loss using essential fatty acid compositions
IE842424L (en) Topical preparations containing tar and fatty acids
MX9207150A (es) Metodo y composiciones para reducir la resistenciaa multiples farmacos.
AU562828B2 (en) Morphine-vitamin b12 analgesic treatment
MY129218A (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
DE59609482D1 (de) Anellierte beta-carboline

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 347056

Country of ref document: ES